medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2009, Number 2

<< Back Next >>

Rev Invest Clin 2009; 61 (2)

Axonal growth inhibition by chondroitin sulfate proteoglycans in the central nervous system

Díaz-Martínez NE, Velasco I

Language: Spanish
References: 55
Page: 140-149
PDF size: 143.36 Kb.


ABSTRACT

Chondroitin sulphate proteoglycans (CSPG) are components of the extracellular matrix, consisting of peptides chemically attached covalently to chains of glycosaminoglycans. There are 4 families of CSPG including lecticans, which are found mainly in the central nervous system (CNS) of vertebrates. In vitro studies have shown a negative effect of these proteoglycans on axonal growth, mediated by depolymerization of actin filaments in the neuronal cytoskeleton. In some neurodegenerative diseases, and especially after traumatic injuries of adult CNS, there are increased levels of CSPG expression. Axonal growth inhibition by CSPG has been observed also in vivo, and therefore a strategy aimed to counteract the inhibition of axonal growth might lead to new therapies designed to restore neural circuits. There is compelling in vivo evidence that CSPG degradation by Chondroitinase ABC allows both axonal growth and functional recovery in models of injury in the mammalian CNS. These data suggest that manipulation of the response to damage could result in effective ways to promote recovery of nerve functions in neurological disorders that affect humans, such as spinal cord lesions or Parkinson disease.


REFERENCES

  1. Schwartz NB, Domowicz M. Proteoglycans in brain development. Glycoconj J 2004; 21: 329-41.

  2. Galtrey CM, Fawcett JW. The role of chondroitin sulfate proteoglycans in regeneration and plasticity in the central nervous system. Brain Res Rev 2007; 54: 1-18.

  3. Oohira A, Matsui F, Tokita Y, et al. Molecular interactions of neural chondroitin sulfate proteoglycans in the brain development. Arch Biochem Biophys 2000; 374: 24-34.

  4. Rauch U. Brain matrix: structure, turnover and necessity. Biochem Soc Trans 2007; 35: 656-60.

  5. Milev P, Maurel P, Chiba A, et al. Differential regulation of expression of hyaluronan-binding proteoglycans in developing brain: aggrecan, versican, neurocan, and brevican. Biochem Biophys Res Commun 1998; 247: 207-12.

  6. Melendez-Vasquez C, Carey DJ, Zanazzi G, et al. Differential expression of proteoglycans at central and peripheral nodes of Ranvier. Glia 2005; 52: 301-08.

  7. Cattaruzza S, Perris R. Approaching the proteoglycome: molecular interactions of proteoglycans and their functional output. Macromol Biosci 2006; 6: 667-80.

  8. Filbin MT. Myelin-associated inhibitors of axonal regeneration in the adult mammalian CNS. Nat Rev Neurosci 2003; 4: 703-13.

  9. Matsui F, Kakizawa H, Nishizuka M, et al. Changes in the amounts of chondroitin sulfate proteoglycans in rat brain after neonatal hypoxia-ischemia. J Neurosci Res 2005; 81: 837-45.

  10. Polito A, Reynolds R. NG2-expressing cells as oligodendrocyte progenitors in the normal and demyelinated adult central nervous system. J Anat 2005; 207: 707-16.

  11. Properzi F, Asher RA, Fawcett JW. Chondroitin sulphate proteoglycans in the central nervous system: changes and synthesis after injury. Biochem Soc Trans 2003; 31: 335-6.

  12. Viapiano MS, Matthews RT. From barriers to bridges: chondroitin sulfate proteoglycans in neuropathology. Trends Mol Med 2006; 12: 488-96.

  13. Ruoslahti E. Brain extracellular matrix. Glycobiology 1996; 6: 489-92.

  14. Rhodes KE, Fawcett JW. Chondroitin sulphate proteoglycans: preventing plasticity or protecting the CNS? J Anat 2004; 204: 33-48.

  15. Friedlander DR, Milev P, Karthikeyan L, et al. The neuronal chondroitin sulfate proteoglycan neurocan binds to the neural cell adhesion molecules Ng-CAM/L1/NILE and N-CAM, and inhibits neuronal adhesion and neurite outgrowth. J Cell Biol 1994; 125: 669-80.

  16. Aono S, Tokita Y, Shuo T, et al. Glycosylation site for chondroitin sulfate on the neural part-time proteoglycan, neuroglycan C. J Biol Chem 2004; 279: 46536-41.

  17. Bandtlow CE, Zimmermann DR. Proteoglycans in the developing brain: new conceptual insights for old proteins. Physiol Rev 2000; 80: 1267-90.

  18. Engel M, Maurel P, Margolis RU, et al. Chondroitin sulfate proteoglycans in the developing central nervous system. I. cellular sites of synthesis of neurocan and phosphacan. J Comp Neurol 1996; 366: 34-43.

  19. Bourdon MA, Krusius T, Campbell S, et al. Identification and synthesis of a recognition signal for the attachment of glycosaminoglycans to proteins. Proc Natl Acad Sci U S A 1987; 84: 3194-8.

  20. Sundblad G, Holojda S, Roux L, et al. Sulfated N-linked oligosaccharides in mammalian cells. II. Identification of glycosaminoglycan- like chains attached to complex-type glycans. J Biol Chem 1988; 263: 8890-6.

  21. Grumet M, Milev P, Sakurai T, et al. Interactions with tenascin and differential effects on cell adhesion of neurocan and phosphacan, two major chondroitin sulfate proteoglycans of nervous tissue. J Biol Chem 1994; 269: 12142-6.

  22. Yamaguchi Y. Lecticans: organizers of the brain extracellular matrix. Cell Mol Life Sci 2000; 57: 276-89.

  23. Hagihara K, Miura R, Kosaki R, et al. Immunohistochemical evidence for the brevican-tenascin-R interaction: colocalization in perineuronal nets suggests a physiological role for the interaction in the adult rat brain. J Comp Neurol 1999; 410: 256-64.

  24. Rahmani M, Wong BW, Ang L, et al. Versican: signaling to transcriptional control pathways. Can J Physiol Pharmacol 2006; 84: 77-92.

  25. Filmus J, Selleck SB. Glypicans: proteoglycans with a surprise. J Clin Invest 2001; 108: 497-501.

  26. De Cat B, David G. Developmental roles of the glypicans. Semin Cell Dev Biol 2001; 12: 117-25.

  27. Saunders S, Paine-Saunders S, Lander AD. Expression of the cell surface proteoglycan glypican-5 is developmentally regulated in kidney, limb, and brain. Dev Biol 1997; 190: 78-93.

  28. Carey DJ. Syndecans: multifunctional cell-surface co-receptors. Biochem J 1997; 327(Pt. 1): 1-16.

  29. Rapraeger AC, Ott VL. Molecular interactions of the syndecan core proteins. Curr Opin Cell Biol 1998; 10: 620-8.

  30. Zimmermann P, David G. The syndecans, tuners of transmembrane signaling. Faseb J 1999; 13(Suppl.): S91-S100.

  31. Maurel P, Rauch U, Flad M, et al. Phosphacan, a chondroitin sulfate proteoglycan of brain that interacts with neurons and neural cell-adhesion molecules, is an extracellular variant of a receptor-type protein tyrosine phosphatase. Proc Natl Acad Sci U S A 1994; 91: 2512-16.

  32. Silver J, Miller JH. Regeneration beyond the glial scar. Nat Rev Neurosci 2004; 5: 146-56.

  33. Fawcett JW. Overcoming inhibition in the damaged spinal cord. J Neurotrauma 2006; 23: 371-83.

  34. Mueller BK, Mack H, Teusch N. Rho kinase, a promising drug target for neurological disorders. Nat Rev Drug Discov 2005; 4: 387-98.

  35. Yiu G, He Z. Glial inhibition of CNS axon regeneration. Nat Rev Neurosci 2006;7:617-627.

  36. Fernaud-Espinosa I, Nieto-Sampedro M, Bovolenta P. A neurite outgrowth-inhibitory proteoglycan expressed during development is similar to that isolated from adult brain after isomorphic injury. J Neurobiol 1998; 36: 16-29.

  37. Asher RA, Morgenstern DA, Fidler PS, et al. Neurocan is upregulated in injured brain and in cytokine-treated astrocytes. J Neurosci 2000; 20: 2427-38.

  38. Schwab ME, Kapfhammer JP, Bandtlow CE. Inhibitors of neurite growth. Annu Rev Neurosci 1993; 16: 565-95.

  39. Milev P, Friedlander DR, Sakurai T, et al. Interactions of the chondroitin sulfate proteoglycan phosphacan, the extracellular domain of a receptor-type protein tyrosine phosphatase, with neurons, glia, and neural cell adhesion molecules. J Cell Biol 1994; 127: 1703-15.

  40. Busch SA, Silver J. The role of extracellular matrix in CNS regeneration. Curr Opin Neurobiol 2007; 17: 120-7.

  41. Gates MA, Fillmore H, Steindler DA. Chondroitin sulfate proteoglycan and tenascin in the wounded adult mouse neostriatum in vitro: dopamine neuron attachment and process outgrowth. J Neurosci 1996; 16: 8005-18.

  42. Laabs TL, Wang H, Katagiri Y, et al. Inhibiting glycosaminoglycan chain polymerization decreases the inhibitory activity of astrocyte-derived chondroitin sulfate proteoglycans. J Neurosci 2007; 27: 14494-501.

  43. Davies SJ, Fitch MT, Memberg SP, et al. Regeneration of adult axons in white matter tracts of the central nervous system. Nature 1997; 390: 680-3.

  44. Davies SJ, Goucher DR, Doller C, et al. Robust regeneration of adult sensory axons in degenerating white matter of the adult rat spinal cord. J Neurosci 1999; 19: 5810-22.

  45. McKeon RJ, Jurynec MJ, Buck CR. The chondroitin sulfate proteoglycans neurocan and phosphacan are expressed by reactive astrocytes in the chronic CNS glial scar. J Neurosci 1999; 19: 10778-88.

  46. Moon LD, Asher RA, Fawcett JW. Limited growth of severed CNS axons after treatment of adult rat brain with hyaluronidase. J Neurosci Res 2003; 71: 23-37.

  47. Perosa SR, Porcionatto MA, Cukiert A, et al. Glycosaminoglycan levels and proteoglycan expression are altered in the hippocampus of patients with mesial temporal lobe epilepsy. Brain Res Bull 2002; 58: 509-16.

  48. DeWitt DA, Silver J, Canning DR, et al. Chondroitin sulfate proteoglycans are associated with the lesions of Alzheimer’s disease. Exp Neurol 1993; 121: 149-52.

  49. DeWitt DA, Richey PL, Praprotnik D, et al. Chondroitin sulfate proteoglycans are a common component of neuronal inclusions and astrocytic reaction in neurodegenerative diseases. Brain Res 1994; 656: 205-9.

  50. Mingorance A, Sole M, Muneton V, et al. Regeneration of lesioned entorhino-hippocampal axons in vitro by combined degradation of inhibitory proteoglycans and blockade of Nogo-66/NgR signaling. Faseb J 2006; 20: 491-3.

  51. Bradbury EJ, Moon LD, Popat RJ, et al. Chondroitinase ABC promotes functional recovery after spinal cord injury. Nature 2002; 416: 636-40.

  52. Barritt AW, Davies M, Marchand F, et al. Chondroitinase ABC promotes sprouting of intact and injured spinal systems after spinal cord injury. J Neurosci 2006; 26: 10856-67.

  53. Garcia-Alias G, Lin R, Akrimi SF, et al. Therapeutic time window for the application of chondroitinase ABC after spinal cord injury. Exp Neurol 2008; 210: 331-8.

  54. Tom VJ, Houle JD. Intraspinal microinjection of chondroitinase ABC following injury promotes axonal regeneration out of a peripheral nerve graft bridge. Exp Neurol 2008; 211: 315-19.

  55. Lin R, Kwok JC, Crespo D, et al. Chondroitinase ABC has a long-lasting effect on chondroitin sulphate glycosaminoglycan content in the injured rat brain. J Neurochem 2008; 104: 400-08.




2020     |     www.medigraphic.com